(2S,4R)-1-benzyloxycarbonyl-4-methanesulfonyloxy-2-[(2-ureidoethyl)oxymethyl]pyrrolidine | 117811-83-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2S,4R)-1-benzyloxycarbonyl-4-methanesulfonyloxy-2-[(2-ureidoethyl)oxymethyl]pyrrolidine
• 英文别名: benzyl (2S,4R)-2-[2-(carbamoylamino)ethoxymethyl]-4-methylsulfonyloxypyrrolidine-1-carboxylate
• CAS: 117811-83-3
• 化学式: C₁₇H₂₅N₃O₇S
• 分子量: 415.467
• InChiKey: IIJPCQSUQOOLEM-LSDHHAIUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  28
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  146
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  (2S,4R)-1-benzyloxycarbonyl-4-methanesulfonyloxy-2-[(2-ureidoethyl)oxymethyl]pyrrolidine 在 钯 盐酸 作用下， 以 甲醇 为溶剂， 生成 (2S,4R)-4-methanesulfonyloxy-2-[(2-ureidoethyl)oxymethyl]pyrrolidine
  参考文献：
  名称：

  3-pyrrolidinylthio-1-azabicyclo(3.2.0)-hept-2-ene-2-carboxylic acid

  摘要：

  这项发明包括3-吡咯烷基巯基-1-氮杂双环[3.2.0]庚-2-烯-2-羧酸化合物及其用作治疗传染病的抗菌剂的应用。

  公开号：

  US04822787A1
• 作为产物：
  描述：

  (2S,4R)-Cbz-4-甲磺酰氧基脯氨酸甲酯 在 sodium hydroxide 、 sodium tetrahydroborate 、 三氟化硼乙醚 、 potassium tert-butylate 、 氨 、 三乙胺 作用下， 以 四氢呋喃 、 乙醇 、 水 为溶剂， 反应 6.0h， 生成 (2S,4R)-1-benzyloxycarbonyl-4-methanesulfonyloxy-2-[(2-ureidoethyl)oxymethyl]pyrrolidine
  参考文献：
  名称：

  Synthesis and antibacterial activity of novel 4-pyrrolidinylthio carbapenems—I. 2-alkoxymethyl derivatives

  摘要：

  The synthesis and in vitro antibacterial activity of a novel series of 2-alkoxymethyl-4-pyrrolidinylthio-1 beta-methyl carbapenems are described. As a result of these studies, we discovered that FR27743 (19j) containing a novel,2-fluoroethoxymethyl substituent possesses a broad spectrum of antibacterial activity against both Gram-positive and Gram-negative organisms, including Pseudomonas aeruginosa. Furthermore, FR27743 exhibited excellent stability against renal dehydropeptidase-I (DHP-I), good urinary recovery, and superior in vivo activity compared to that for Meropenem against several systemic infections. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0968-0896(97)00142-9

文献信息

• 3-pyrrolidinylthio-1-azabicyclo(3.2.0)-hept-2-ene-2-carboxylic acid
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US04822787A1

  公开（公告）日：1989-04-18

  This invention consists of 3-pyrrolidinylthio-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid compounds and their use as antimicrobial agents in the treatment of infectious diseases.

  这项发明包括3-吡咯烷基巯基-1-氮杂双环[3.2.0]庚-2-烯-2-羧酸化合物及其用作治疗传染病的抗菌剂的应用。
• 3-Pyrrolidinylthio-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid compounds and processes for the preparation thereof
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0272456A1

  公开（公告）日：1988-06-29

  A compound of the formula : in which R1 is carboxy or protected carboxy, R2 is hydroxy(lower)alkyl or protected hydroxy(lower)alkyl, R3 is hydrogen or lower alkyl, R4 is protected or unprotected ureido(lower)alkyl, R5 is hydrogen, lower alkanimidoyl or imino-protective group, and A is lower alkylene, and pharmaceutically acceptable salts thereof, processes or their preparation and pharmaceutical compositions comprising them. The invention also relates to intermediate compounds of the formula

  式.的化合物 其中 R1 为羧基或受保护的羧基、 R2 是羟基（低级）烷基或受保护的羟基（低级）烷基 R3 是氢或低级烷基 R4 是受保护或未受保护的脲基（低级）烷基、 R5 是氢、低级烷酰基或亚氨基保护基团，以及 A 是低级亚烷基，及其药学上可接受的盐、制备工艺或包含它们的药物组合物。本发明还涉及式中的中间体化合物
• US4822787A
  申请人：——

  公开号：US4822787A

  公开（公告）日：1989-04-18
• Synthesis and antibacterial activity of novel 4-pyrrolidinylthio carbapenems—I. 2-alkoxymethyl derivatives
  作者：Hidenori Azami、Hideo Tsutsumi、Keiji Matsuda、David Barrett、Kouji Hattori、Takashi Nakajima、Satoru Kuroda、Toshiaki Kamimura、Masayoshi Murata

  DOI：10.1016/s0968-0896(97)00142-9

  日期：1997.11

  The synthesis and in vitro antibacterial activity of a novel series of 2-alkoxymethyl-4-pyrrolidinylthio-1 beta-methyl carbapenems are described. As a result of these studies, we discovered that FR27743 (19j) containing a novel,2-fluoroethoxymethyl substituent possesses a broad spectrum of antibacterial activity against both Gram-positive and Gram-negative organisms, including Pseudomonas aeruginosa. Furthermore, FR27743 exhibited excellent stability against renal dehydropeptidase-I (DHP-I), good urinary recovery, and superior in vivo activity compared to that for Meropenem against several systemic infections. (C) 1997 Elsevier Science Ltd.